MTOR and cholangiocarcinoma: Further, we demonstrate that miR-199a-3p could increase the cisplatin sensitivity of cholangiocarcinoma cell lines by inhibiting the activity of the mTOR signaling pathway, decreasing the synthesis of MDR1, and increasing the degradation of MDR1.